Diffuse Fasciitis with Eosinophilia Associated with Morphea and Lichen sclerosus et atrophicus

HARTWIG MENSING and KLAUS-ULLRICH SCHMIDT

Department of Dermatology, University of Hamburg, Hamburg, Federal Republic of Germany

Diffuse fasciitis with eosinophilia (DFE) was first described as an entity 1974 by Shulman et al. (1). Since then nearly 100 cases have been reported in the world literature (2, 3, 4). Although some negative criteria of DFE are suitable to separate this disease from progressive systemic scleroderma (PSS), there is so far no general agreement to classify the disease within the group of connective tissue diseases. We report here on two cases of DFE, both associated with morphea, in one case additionally linked with lichen sclerosus et atrophicus.

CASE REPORT
1. A 45-year-old woman suddenly became aware of swollen forearms. A short time later the edema was replaced by a more indurated, fibrous hardening of the tissue. The indurations spread during the next months over nearly the whole body leaving only the face unaffected. She had never recognized periods of Raynaud’s phenomenon, nor had she subsequently developed any internal manifestation as seen in PSS. Laboratory examinations uncovered an increased ESR (40–70/1h) and 15–25 % eosinophilic granulocytes in the differential blood count. Other findings were in normal range. The diagnosis of DFE was ensured by a deep biopsy including the fascia and adjacent muscle. One year later morphea-like lesions appeared in the region of the breast and neck. The forearms and thighs developed a lilac-coloured inflammation resembling linear morphea in this area and the histological examination confirmed the diagnosis of morphea.

At the same time overall induration of the skin increased and a low-dose corticosteroid therapy (40 mg prednisolone/day) was started. All indurated lesions as well as both types of morphea-like lesions improved. Some weeks after finishing the steroid therapy a slow impairment of the lesions was observed. Relapses occurred for several times after increasing and reducing the dose of steroids.
Fig. 1. Back of patient 2. Widespread burned-out morphea plaques and disseminated "white spot disease" (lichen sclerosus).

Fig. 2. Forearm and hand of patient 2. Swelling of the forearm and handwrist. Arrow: site of biopsy.

Fig. 3. Biopsy specimen obtained from the forearm of patient 2 (see arrow Fig. 2). Inflammatory reaction in the adjacent muscle consisting of lymphocytes, neutrophils and eosinophils (arrows). In part complete destruction of the muscle architecture by the inflammatory process.
2. A 41-year-old woman had a long history of nearly generalized, burned-out morphea and a disseminated lichen sclerosus et atrophicus (Fig. 1). The nature of both lesions was confirmed by histological examination several years before. This patient now developed swelling of both wrists and distal forearms behind the circular, hyperpigmented morphea lesions (Fig. 2). Laboratory findings were largely in normal range except an elevated ESR (35 mm/1h) and a slight increase of eosinophils (6-12%) in the periphery blood. Histologic examination of a biopsy obtained from the forearm lesion (arrow in Fig. 2) showed a nearly unchanged dermis and subcutis under the hyperpigmented basal line of the epidermis. The fascia and, more pronounced, the adjacent muscle were involved by an inflammatory infiltrate (Fig. 3). The fascia was moderately thickened. The muscle fibers showed a strong degeneration. Only the empty cover of the sarcolemma was sometimes traceable (Fig. 3). Treatment with corticosteroids (20 mg prednisolone/day) lead to an improvement of the swelling and reduction of the strangled feeling in the forearms.

DISCUSSION

Diagnosis of DFE can only be established by a deep skin biopsy including fascia and adjacent muscle (2). Thickening of the fascia and inflammatory reactions containing lymphocytes, neutrophils, plasma cells, mast cells and (not necessarily) eosinophils were present in both patients. Clinical symptoms together with the laboratory findings ensured the diagnosis of DFE in both patients. Association of DFE with other diseases are mainly described with respect to hematologic disorders like aplastic anemia (5), immune thrombocytopenia or Hodgkin’s disease (6). In none of the two patients hematologic abnormalities could be detected. Morphea-like skin changes were, however, observed in each. In the first patient morphea occurred after the first manifestation of DFE. Corticosteroid therapy achieved positive results in the widespread DFE and morphea lesions. On the other hand, a long lasting complete remission could not be achieved as relapses of morphea and DFE occurred several times over a follow-up period of two years.

In contrast to the first patient, the manifestation of a nearly generalized morphea appeared in the second patient long before the DFE lesions were noted. Simultaneously with the morphea, lichen sclerosus et atrophicus was observed in this patient. To our knowledge only one case of coincidence of DFE and severe generalized morphea has been reported previously (7). But in spite of undeniable, clinical and laboratory findings the authors did not believe that their patient really suffered from DFE. Recently the direct transformation of previously DFE-like appearing lesions into PSS within three months has been described (7). Accordingly late occurring internal involvement cannot be ruled out in other cases (8). There are, however two facts that distinguish DFE from PSS: the good prognosis in most of the reported patients without involvement of internal organs during a long-time follow-up and the above mentioned better response to therapy. This supports the assumption of an exceptional position of DFE in the class of connective tissue disorders. Moreover, the findings in nailfold capillaroscopy (9) and the proof of eosinophilic chemo- tactic factor in the serum of DFE patients (10) support its position as an own entity. The two patients suffered from symptoms clearly connected with DFE. The association with morphea and lichen sclerosus, two other disorders of connective tissue with unknown etiology, points to a close relationship between disorders affecting the connective tissue. Therefore DFE as an own entity should be kept in mind in discussions until further evidence will be presented allowing to give an affirmative answer to the question of Shulman in his first report (1): Diffuse fasciitis with eosinophilia and hypergammaglobulinemia— a new syndrome?

ACKNOWLEDGEMENT

This work was supported by Deutsche Forschungs-Gemeinschaft, Me 766-2/1.
REFERENCES


Radiographic Bone Surveys after Isotretinoin Therapy for Cystic Acne

CHARLES N. ELLIS,1,2 DAVID R. PENNES,2,4 WILLIAM MARTEL2 and JOHN J. VOORHEES1

1Clinical Pharmacology Unit of the Department of Dermatology, University of Michigan Medical School, 2Department of Radiology, University of Michigan Medical School, and the 3Dermatology and 4Radiology Services, Veterans Administration Medical Center, Ann Arbor, Michigan, USA


Seven patients underwent retrospective radiographic examination 10 to 16 months after high dose isotretinoin therapy for severe cystic acne. One patient, who received the highest isotretinoin dose (approximately twice the average dose taken by the remaining patients), had multiple small hyperostoses of the thoracic spine and tarsi navicular. These findings were identical to the skeletal changes known to occur during retinoid administration. Prospective studies are needed to ascertain the risk of developing hyperostoses during isotretinoin therapy for acne at the lower doses currently employed. In this preliminary study, clinically significant hyperostoses were not a late sequela of high dose isotretinoin treatment for acne. Key words: Retinoids; 13-Cis-retinoic acid; Hyperostosis. (Received August 31, 1984.)

C. N. Ellis, Dermatology Service (110), Veterans Administration Medical Center, 2215 Fuller Rd., Ann Arbor, MI 48105, USA.

The development of hyperostoses during isotretinoin therapy for ichthyosis was first described by Pittsley & Yoder (1) and investigated prospectively by us (2, 3). We have determined that as few as six months of isotretinoin administration at doses required for the treatment of disorders of keratinization may cause hyperostoses, particularly in the spine. These findings have generated concern among clinicians that patients taking isotretinoin for severe acne may develop hyperostoses, although at the time of this writing, no such cases have been reported.

To determine if isotretinoin, at doses used to treat severe cystic acne, causes the